Eli Lilly commits $100M upfront in new five-target partnership with China's InnoCare

Eli Lilly has agreed to pay $100 million upfront and in the near term to Chinese biotech InnoCare Pharma as part of a five‑target drug discovery partnership. The agreement also provides for up to $3.25 billion in potential milestone payments as the programs progress.

InnoCare will apply its discovery platform and research expertise to the five undisclosed targets, which the companies say address critical unmet medical needs. Details on the therapeutic areas have not been released.

The deal includes development and commercial milestones as well as single‑digit tiered royalties on annual net product sales for any successful products.

The partnership expands Lilly’s recent series of large‑scale collaborations, funded by strong cash flow from its GLP‑1 products and a string of acquisitions exceeding $1 billion each this year.

InnoCare CEO Jasmine Cui noted the company’s ongoing business‑development activities and emphasized that it is not in a hurry to partner its programs.